Limtop is an innovative formulation for treatment of actinic keratosis, genital warts and basal cell cancer. The objective is a product with a short treatment duration, an improved safety profile and an effect similar to or better than that of competing preparations.
Limtop is based on a patent-pending formulation of a proven compound that results in a high and precise dose of the active substance being transported into the skin. The company's preclinical results show that Limtop has a far greater capacity than existing preparations to transport the active substance to the target tissue in the skin.
Actinic keratosis is sun damage that is characterised by thickening of the horny layer of the epidermis. The condition has become more common as a result of changed lifestyle and increased exposure to strong sunlight. Actinic keratosis can develop into squamous cell carcinoma and should thus be treated. Prevalence varies, as fair-skinned individuals are affected more. In populations in the northern hemisphere the prevalence is reported as being between 11% and 25%.
Over a million cases of basal cells cancer are reported every year in the USA and the EU, with an over‑representation in men.
For genital warts an incidence level of 0.2% to 0.4% per year is reported. A sexually active person in the USA has a 50% risk of being infected by genital warts during his/her lifetime.
The market for treatments for actinic keratosis, basal cell cancer and genital warts is estimated to $700m. There is a great need for products with a better safety profile and shorter treatment duration.
Phase II trial ongoing.